Due to system upgrades, please note the following. Orders placed will be processed in 1-2 business days but may incur a slight delay in fulfillment. Learning activities ordered will be available immediately after order placement. CAP is committed to processing orders as quickly and securely as possible during this upgrade. Thank you for your patience.
Program FL9 is intended for laboratories that perform measurable (minimal) residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
Participation in this program alone does not satisfy PT requirements for laboratories performing more general analysis of leukemia/lymphoma specimens.
Program Information
Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma measurable (minimal) residual disease
One online case consisting of gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
Help